Vermorken JB - Search Results

1

Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.

van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ. van Moorsel CJ, et al. Among authors: vermorken jb. Eur J Cancer. 1999 May;35(5):808-14. doi: 10.1016/s0959-8049(99)00004-0. Eur J Cancer. 1999. PMID: 10505043

2

Phase I study of spiroplatin.

Tanis BC, Vermorken JB, ten Bokkel Huinink WW, Klein I, Gall H, van Oosterom AT, Simonetti G, McVie JG, van der Vijgh WJ, Pinedo HM. Tanis BC, et al. Among authors: vermorken jb. Eur J Cancer. 1991;27(3):268-73. doi: 10.1016/0277-5379(91)90513-d. Eur J Cancer. 1991. PMID: 1827311 Clinical Trial.

3

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.

Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ. Ruiz van Haperen VW, et al. Among authors: vermorken jb. Biochem Pharmacol. 1994 Oct 7;48(7):1327-39. doi: 10.1016/0006-2952(94)90554-1. Biochem Pharmacol. 1994. PMID: 7945430

4

Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ. Ruiz van Haperen VW, et al. Among authors: vermorken jb. Cancer Res. 1994 Aug 1;54(15):4138-43. Cancer Res. 1994. PMID: 8033147

5

Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.

Ruiz van Haperen VW, Veerman G, Braakhuis BJ, Vermorken JB, Boven E, Leyva A, Peters GJ. Ruiz van Haperen VW, et al. Among authors: vermorken jb. Eur J Cancer. 1993;29A(15):2132-7. doi: 10.1016/0959-8049(93)90048-k. Eur J Cancer. 1993. PMID: 8297652

6

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.

Ruiz van Haperen VW, Veerman G, Vermorken JB, Peters GJ. Ruiz van Haperen VW, et al. Among authors: vermorken jb. Biochem Pharmacol. 1993 Aug 17;46(4):762-6. doi: 10.1016/0006-2952(93)90566-f. Biochem Pharmacol. 1993. PMID: 8363650

7

Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.

van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters G. van Haperen VW, et al. Among authors: vermorken jb. Biochem Pharmacol. 1996 Apr 12;51(7):911-8. doi: 10.1016/0006-2952(95)02402-6. Biochem Pharmacol. 1996. PMID: 8651941

8

Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.

Veerman G, Ruiz van Haperen VW, Vermorken JB, Noordhuis P, Braakhuis BJ, Pinedo HM, Peters GJ. Veerman G, et al. Among authors: vermorken jb. Cancer Chemother Pharmacol. 1996;38(4):335-42. doi: 10.1007/s002800050492. Cancer Chemother Pharmacol. 1996. PMID: 8674156

9

Combination chemotherapy studies with gemcitabine.

van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, Peters GJ. van Moorsel CJ, et al. Among authors: vermorken jb. Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-17-S7-23. Semin Oncol. 1997. PMID: 9194475 Review.

10

Mechanisms of synergism between gemcitabine and cisplatin.

van Moorsel CJ, Veerman G, Vermorken JB, Voorn DA, Kroep JR, Bergman AM, Pinedo HM, Peters GJ. van Moorsel CJ, et al. Among authors: vermorken jb. Adv Exp Med Biol. 1998;431:581-5. doi: 10.1007/978-1-4615-5381-6_112. Adv Exp Med Biol. 1998. PMID: 9598132 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

560 results

Search Page

Filters